Opiate Alkaloid Hydrogenation via Aprotic Solvent and One-Pot Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic routes for producing buprenorphine from thebaine are inefficient, requiring excessive reaction time, generating hazardous byproducts, and resulting in low yields due to the need for complex purification steps and handling of toxic substances like methyl vinyl ketone.
Innovation Solution
A one-pot process using an aprotic solvent like isopropyl acetate for both the Diels-Alder and hydrogenation reactions, which reduces reaction time, increases yield, and minimizes the handling of hazardous substances by converting methyl vinyl ketone to a less toxic compound, while allowing for crystallization of the product in a pure form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If thebaine is reacted with excess methyl vinyl ketone in a Diels-Alder step followed by hydrogenation, then buprenorphine can be produced, but the reaction time is excessively high (30 hours for hydrogenation alone) and the yield is low (80%)
Solution Approach 1:
The patent changes the solvent parameter from protic (methanol, ethanol) to aprotic (ethyl acetate, isopropyl acetate, toluene). This parameter change accelerates the hydrogenation reaction rate while improving the yield to 92-96%, resolving the contradiction between reaction time and product yield
Solution Approach 2:
The patent extracts and removes the excess methyl vinyl ketone after the Diels-Alder reaction through distillation under reduced pressure before proceeding to hydrogenation. This eliminates the need to handle large amounts of toxic substance during hydrogenation and prevents side reactions that would reduce yield
2Manufacturing precision
If excess methyl vinyl ketone is removed by distillation and the product is recrystallized from boiling methanol, then purification is achieved, but the process complexity increases and worker exposure to hazardous substances increases
Solution Approach 1:
The patent converts the harmful excess methyl vinyl ketone into beneficial 2-butanone through hydrogenation. The toxic dienophile is transformed into a less hazardous saturated ketone, eliminating worker exposure risks while simplifying the process by removing the need for separate purification steps
Solution Approach 2:
The patent merges the Diels-Alder reaction and hydrogenation into a one-pot process. The hydrogenation step simultaneously reduces the excess methyl vinyl ketone and hydrogenates the Diels-Alder adduct, eliminating the need for separate purification steps and reducing process complexity
3Productivity
If protic solvents like methanol or ethanol are used for hydrogenation, then the reaction can proceed, but the reaction time is long and the yield is reduced due to epimeric impurity formation
Solution Approach 1:
The patent changes the solvent parameter from protic to aprotic, which eliminates epimeric impurity formation and accelerates the hydrogenation reaction. This single parameter change simultaneously improves both reaction rate and product purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process significantly reduces overall reaction time by over 50%, increases product yield and purity, and eliminates the need for complex purification steps, making it safer and more efficient for producing buprenorphine and other biologically active alkaloids.
Implementation Method 1
contacting the compound comprising Formula (II) with a transition metal catalyst, hydrogen gas and the aprotic solvent to form a compound comprising Formula (III)
Implementation Method 2
The Diels Alder product is then hydrogenated to produce 7-acetyl-6,14-endoethano-6,7,8,14-tetrahydrothebaine
Data Source
AI summary
The present invention provides processes for the synthesis of opiate alkaloids. In particular, the opiate alkaloids produced by the process of the invention are typically intermediate compounds that may be utilized to produce a variety of biologically active alkaloids including buprenorphine and diprenorphine.